By Suherman Candra Maholtra 
Researchers at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health have achieved a significant milestone in the global fight against tuberculosis (TB) by developing an experimental therapeutic DNA vaccine designed for intranasal delivery. This novel vaccine specifically targets "persisters"—a subpopulation of drug-tolerant TB bacteria that often survive conventional, long-term antibiotic treatments and are responsible for disease relapse. By leveraging a unique genetic fusion and a localized delivery method, the research team aims to provide a powerful tool to complement existing drug therapies, potentially shortening treatment durations and curbing the rise of drug-resistant strains. The findings, recently published in the Journal of Clinical Investigation, represent a critical step toward a more effective immunotherapy for a disease that has plagued humanity for millennia.
The Persistent Global Threat of Tuberculosis
Tuberculosis remains a formidable adversary in public health, despite being a preventable and curable disease. Historical evidence suggests that Mycobacterium tuberculosis has afflicted human populations for at least 6,000 years, evolving alongside its host to become one of the most successful pathogens in history. According to the World Health Organization (WHO) 2024 Global Tuberculosis Report, the scale of the crisis remains staggering. Approximately one-quarter of the global population—roughly 2 billion people—is estimated to carry a latent TB infection. While these individuals do not show symptoms and are not contagious, the bacteria remain dormant within their bodies, posing a lifelong risk of reactivation.
In 2024 alone, more than 10 million people developed active tuberculosis, and approximately 1.2 million individuals succumbed to the disease. These statistics underscore TB’s position as the leading cause of death from a single infectious pathogen, often surpassing the mortality rates of HIV/AIDS and malaria. The challenge is exacerbated by the lengthy and arduous nature of TB treatment, which typically requires a combination of antibiotics taken for six to nine months. The difficulty of completing these regimens frequently leads to treatment non-compliance, which in turn fuels the emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB).
The Science of Bacterial Persistence
The primary hurdle in treating tuberculosis is the phenomenon of bacterial persistence. When exposed to the hostile environment of the human immune system or the stress of antibiotic therapy, a portion of the TB bacterial population enters a state of metabolic dormancy. These "persisters" are not necessarily resistant to drugs through genetic mutations; rather, they are drug-tolerant because they are no longer actively dividing, which is the stage at which most antibiotics are effective.
"TB bacteria possess a gene, relMtb, that produces a protein, RelMtb, to help the microbes survive hostile conditions such as antibiotic exposure, low oxygen, and nutrient limitation by entering a drug-tolerant persistent state," explained study lead author Styliani Karanika, M.D., an assistant professor of medicine at the Johns Hopkins University School of Medicine. Once the course of antibiotics is completed or interrupted, these persisters can "wake up," resume replication, and cause a clinical relapse, necessitating further rounds of even more intensive treatment.
Engineering a Targeted DNA Vaccine
To address this challenge, the Johns Hopkins team developed a DNA vaccine that employs a "prime and pull" strategy to alert the immune system to these hidden bacteria. The vaccine is a genetic fusion of two specific components: the relMtb gene and the Mip3α gene.
The inclusion of the relMtb gene ensures that the immune system is trained to recognize the specific protein associated with the dormant state of the bacteria. However, simply introducing this antigen is often insufficient to trigger a robust response. To solve this, the researchers fused it with Mip3α (Macrophage Inflammatory Protein-3 alpha), a signaling protein.
"Fusing relMtb with the Mip3α gene produces a signal that attracts immature dendritic cells," Karanika noted. Dendritic cells serve as the "sentinels" of the immune system; they capture foreign proteins and present them to T cells, which are the primary executors of the body’s targeted immune response. By attracting these cells directly to the site of the vaccine, the researchers essentially created a biological beacon that ensures the immune system identifies the TB persisters as a threat.
The Strategic Advantage of Intranasal Delivery
While many vaccines are administered via intramuscular injection, the Johns Hopkins team opted for an intranasal delivery method. This choice is rooted in the fundamental biology of tuberculosis, which is primarily a respiratory infection. By delivering the vaccine through the nose, the researchers are able to target the respiratory mucosa—the specialized tissue lining the lungs and airways where TB bacteria first gain a foothold.
This localized approach helps generate long-lasting, localized T-cell immunity in the lungs, creating a front-line defense at the point of entry. Furthermore, the study demonstrated that this method also triggers systemic immune responses, providing a multi-layered shield throughout the body. This dual-action immunity—both local and systemic—is considered a "holy grail" in the development of respiratory vaccines.
Experimental Results: Success in Mouse and Primate Models
The efficacy of the experimental vaccine was first tested in mouse models. The results were highly encouraging: when administered alongside first-line TB drug therapy, the vaccine significantly accelerated the clearance of the bacteria. Mice receiving the vaccine showed a marked reduction in lung inflammation compared to those receiving drugs alone. Most importantly, the vaccine was effective in preventing disease relapse after the treatment period ended, addressing the core issue of bacterial persistence.
The study also examined the vaccine’s performance in conjunction with the "BPaL" regimen—a potent combination of bedaquiline, pretomanid, and linezolid used to treat highly drug-resistant TB. The data suggested that the vaccine enhanced the effectiveness of these drugs, offering a potential lifeline for patients with hard-to-treat, drug-resistant infections.
Following the success in mice, the researchers transitioned to rhesus macaques to evaluate the vaccine’s translational potential. In these primates, the intranasal DNA vaccine generated measurable, TB-specific immune responses in both the bloodstream and the airways. These responses were consistent with those observed in the mice that successfully cleared the infection. Critically, the immune activation in the macaques lasted for at least six months, indicating that the vaccine could provide durable, long-term protection.
Analyzing the Broader Impact on Global Health
The development of a therapeutic vaccine aligns with the World Health Organization’s "End TB Strategy," which calls for innovative tools to reduce TB incidence by 90% and deaths by 95% by 2035. Current strategies rely heavily on the BCG (Bacille Calmette-Guérin) vaccine, which was developed in 1921. While BCG is effective in preventing severe forms of TB in children, its efficacy in preventing adult pulmonary TB—the most common form of the disease—is notoriously inconsistent.
The Johns Hopkins DNA vaccine represents a shift toward immunotherapy as a pillar of TB treatment. By focusing on eliminating the bacteria that antibiotics miss, this approach could significantly shorten the standard six-month treatment window. Shortening treatment is not merely a matter of patient convenience; it is a vital public health strategy. Shorter regimens increase the likelihood of treatment completion, reduce the economic burden on healthcare systems, and decrease the opportunities for the bacteria to develop further resistance.
Furthermore, DNA vaccines offer logistical advantages over traditional protein-based or mRNA vaccines. They are generally more stable at higher temperatures and can be produced relatively efficiently, which is a critical consideration for distributing vaccines in the low- and middle-income countries where the TB burden is highest.
Future Directions and Clinical Trials
Despite the promising results, Dr. Karanika emphasizes that more work is required before the vaccine is ready for human use. The primate study, while successful, focused on immune activation rather than protection against an active TB challenge. The next phase of research will involve more rigorous preclinical testing to ensure safety and to further refine the dosage and delivery protocols.
"These nonhuman primate data are encouraging because they show that the Mip3α/relMtb vaccine can generate durable, antigen-stimulated immune responses in an animal model whose immune system more closely resembles that of humans," Karanika stated. "That gives us an important translational bridge between the mouse efficacy studies and the additional preclinical work needed before human trials."
The research was supported by a diverse array of funding sources, including multiple grants from the National Institutes of Health (NIH), the Gilead HIV Research Scholar Award, and the Johns Hopkins University Tuberculosis Research Advancement Center. The collaborative nature of the study, involving experts from infectious disease, pathology, and public health, highlights the multidisciplinary effort required to tackle a pathogen as complex as Mycobacterium tuberculosis.
As the global medical community continues to grapple with the aftermath of the COVID-19 pandemic and the rising threat of antimicrobial resistance, the Johns Hopkins study provides a beacon of hope. By targeting the "persisters" that have allowed tuberculosis to survive for millennia, this new vaccine candidate could finally tip the scales in favor of global eradication. The path from the laboratory to the clinic remains long, but the foundation laid by this research offers a promising new strategy for ending the reign of the world’s deadliest infectious disease.
